CervoMed is trading 11.19% up at $3.18 after its August 10, 2026 earnings highlighted a $6.6 million quarterly loss and extended cash runway into late 2027 through $20.5 million in equity financing.
- Management is focused on securing a strategic partner for neflamapimod’s Phase 3 dementia-with-Lewy-bodies program.
- The company is also presenting at the Canaccord Growth Conference on August 11.